Monthly Archives: August 2021

Ongoing advances in treatment options for patients with lung cancer are spurring patients hopes for life extensions in the face of the nations deadliest cancer. In honor of this years upcoming World Lung Cancer Day, medical oncologist Hamid Mirshahidi, MD, from Loma Linda University Cancer Center, and patient Maribel Padilla spread the word about a type of promising treatment option available to those living with lung cancer.

Though chemotherapy tends to come to mind first as the conventional route for cancer treatment, a slew of targeted therapies perpetually emerging from research and clinical trials are capable of outperforming chemotherapy in groups of patients with specific genetic mutations, Mirshahidi says.

Such was the case for 55-year-old Maribel Padilla, who, before reaching Loma Linda University Health in 2011, was informed she had a year maximum to live with stage four lung cancer that spread to her brain. After undergoing a brain surgery at the initial institution, Padilla transferred to LLU to work with the Cancer Center team and enrolled in three clinical trials. She has celebrated a decade of life since.

Our mindset was to give it a shot because we thought our mom had less than a year to live and we had nothing to lose. Gabriela Castillo

To determine whether Padilla would benefit from targeted therapy, LLU cancer experts conducted a tissue biopsy and analyzed her DNA. Sure enough, Padilla possessed a mutation in the DNA called anaplastic lymphoma kinase (ALK), placing her among the roughly 25% of lung cancer patients with any oncology driver mutation and qualifying her for enrollment in some clinical trials, Mirshahidi said.

Of that 25%, Padilla was among the 5% of patients with ALK specifically a DNA mutation in lung cells that happens when two genes fuse, prompting lung cells to make too many copies of themselves that are cancerous and prone to spread throughout the body.

Padilla and her daughters, Gabriela and Karla Castillo, learned about the clinical trials and ultimately took the leap of faith to enroll. Our mindset was to give it a shot because we thought our mom had less than a year to live and we had nothing to lose," Gabriela said.

Padilla first enrolled in a trial for the drug Crizatinib and experienced minimal side effects. Yet, as lung cancer mutates and moves throughout the body, it may become resistant to one drug and weak to another. Cognizant of this phenomenon, LLU Cancer Centers weekly multidisciplinary team quickly and repeatedly tests for patients mutations and adapts treatment to a new targeted therapy drug.

After about a year on the first drug, Padillas cancer spread to her brain a second time, and her care team promptly enrolled her in a new clinical trial for a drug called Ceratinib. She continued this treatment regimen for years to keep the cancer under control and again experienced minimal adverse reactions relative to what chemotherapy tends to induce.

Ms. Padilla was able to benefit from and prove that those targeted therapy drugs for lung cancer patients with her same mutations are much more beneficial than chemotherapy would have been.Dr. Hamid Mirshahidi

Most recently, Padilla started on Lorlatinib through compassionate use, which occurs when a pharmaceutical company grants a clinical center the ability to provide their patients with a non-FDA-approved drug. Since Padilla completed the clinical trials and started compassionate use, all three targeted therapies have been FDA-approved.

To earn FDA approval, targeted therapies must prove themselves more effective than conventional chemotherapy for a specific group of patients, Mirshahidi said. After one targeted therapy obtains approval, usually a newly created, more potent drug will require another clinical trial, and so on.

Mirshahidi says targeted therapy produces fewer side effects for patients who meet the genetic criteria, proves more thorough and effective for fighting cancer, and offers a better quality of life than traditional chemotherapy. He continues to monitor Padillas response to treatment via various tests like CT scans and MRIs, which show shrinkage of her cancer.

She is now about eight years into treatment with no evidence of recurrence and never tried any conventional IV chemotherapy at LLU, he said. Ms. Padilla was able to benefit from and prove that those targeted therapy drugs for lung cancer patients with her same mutations are much more beneficial than chemotherapy would have been.

Since starting targeted therapy for her lung cancer, Padilla says she has felt grateful to live these past 10 years, during which she met her five newly-born grandchildren and solidified her pre-existing bonds with her other grandchildren.

Meanwhile, advances in targeted therapies forge ahead full-speed while Loma Linda University Heath continues to enhance and hone life-changing treatment plans to optimize lung cancer patients health journeys.

At Loma Linda University Cancer Center, physicians are committed to providing patients with compassionate, comprehensive care that gives them the best opportunity to face and overcome cancer. To learn more about lung cancer care at the Cancer Center, please visit lluh.org/cancer-center/cancer-programs/lung-cancer-care.

View original post here:

Stage IV lung cancer patient enjoys life extension from targeted therapy treatments - Loma Linda University Health

Empty vials of Johnson & Johnson's coronavirus disease (COVID-19) vaccine are seen on a table at a vaccination centre in Ronda, Spain, April 23, 2021. REUTERS/Jon Nazca/File Photo/File Photo

July 28 (Reuters) - The U.S. Food & Drug Administration extended the shelf life for Johnson & Johnson's (JNJ.N) single-shot COVID-19 vaccine to six months from four-and-a-half months, the company said late Wednesday.

The FDA's decision is based on data from ongoing studies, which showed the vaccine is stable at six months when refrigerated at 2 to 8 degrees Celsius (3646 degrees Fahrenheit), the drugmaker said. (https://bit.ly/3ypgpTT)

In a letter to the company, the FDA said it had completed the review of data provided by J&J, and based on the information submitted, it concurs with the extension. (https://bit.ly/3zRuTMB)

The agency also said the extension was applicable to batches that might have expired prior to the issuance of the letter provided they were stored at the recommended temperature.

Reporting by Aakriti Bhalla in Bengaluru; Editing by Shinjini Ganguli and Subhranshu Sahu

Our Standards: The Thomson Reuters Trust Principles.

Read this article:

J&J says U.S. FDA agrees to extend shelf life of its COVID-19 vaccine - Reuters

The new phase II trial, to be funded by The Brain Tumour Charity, will assess whether adding Sativex (an oral spray containing cannabinoids THC and CBD) to chemotherapy could extend life for thousands with a recurrent glioblastoma.

The drug -already used in treating multiple sclerosis -was found to be tolerable in combination with chemotherapy, with the potential to extend survival, in a phase I trial in glioblastomas earlier this year.

The new three-year phase II trial (ARISTOCRAT), led by Professor Susan Short at the University of Leeds and co-ordinated by the Cancer Research UK Clinical Trials Unit at the University of Birmingham, is due to begin recruiting over 230 patients across all UK nations in early 2022, subject to sufficient funds being raised.

Having seen its income drop by over 25% last year due to the pandemic and been forced to pause its regular research grant funding programme, The Brain Tumour Charity has today launched an appeal to raise the 450,000 needed to open the trial as soon as possible.

Experts hope that, should the trial prove successful, Sativex could represent one of the first additions to NHS treatment for glioblastoma patients since temozolomide chemotherapy in 2007.

Glioblastomas are the most common and most aggressive form of brain cancer, with around 2,200 people diagnosed each year in England alone. They are usually fast-growing and diffuse, with poorly-defined boundaries and thread-like tendrils that extend into other parts of the brain.

Almost all glioblastomas recur even after intensive treatment including surgery, radiotherapy and chemotherapy, and average survival is just 12-18 months from first diagnosis.

Over the last decade, there has been significant global interest within both patient and scientific communities about the activity of cannabinoids in brain tumours, with the view that cannabinoid-based products may not only help relieve symptoms but could also have a positive impact on survival.

Several pre-clinical laboratory studies have suggested that cannabinoids THC and CBD may reduce brain tumour cell growth and could disrupt the blood supply to tumours -however, to date, clinical evidence that they could treat brain tumours has been limited.

In this new phase II trial, researchers will assess whether adding Sativex to the current standard chemotherapy treatment (temozolomide) could offer extra time to live for adults diagnosed with a recurrence of their glioblastoma after initial treatment.

The trial plans to recruit 232 participants across a minimum of 15 hospitals: two thirds of the participants will be given temozolomide plus Sativex, while one third will be given temozolomide plus placebo.

Sativex, manufactured by GW Pharma, is an oromucosal spray containing 1:1 THC (Delta-9-tetrahydrocannabinol) and CBD (cannabidiol), with the active ingredients being absorbed in the lining of the mouth, either under the tongue or inside the cheek.

Participants will be asked to administer up to 12 sprays per day (or to the maximum dose they can tolerate if fewer than 12) of Sativex or placebo oral sprays.

Participants will then undergo regular follow-up including clinical assessment (every four weeks), blood tests, MRI scans (every eight weeks), and they will complete quality of life questionnaires. This will also be one of the first trials to integrate with The Brain Tumour Charitys app BRIAN.

The trial will measure whether adding Sativex to chemotherapy extends the overall length of patients lives (overall survival), delays the progression of their disease (progression-free survival) or improves quality of life.

In the initial phase I study, the most common side-effects reported were fatigue, headache, vomiting and nausea, which were mostly classed as being mild-moderate in severity.

Stephen Lee, 62 from Leyland in Lancashire, took part in the phase I trial of Sativex in 2015 after his glioblastoma returned following initial treatment. Stephen was first diagnosed in 2010, just a few months after he had very sadly lost his older brother to the same disease. Stephen said:

My diagnosis was very sudden and was one of those days you never forget. Having had to leave work early with a severe headache and a stabbing pain in my right eye, my wife insisted that we go straight to hospital after what my brother had experienced.

I was admitted that same day, had a scan and thats when they identified it was a brain tumour. I had the operation the following week, and beforehand my wife and I agreed that we wanted to stay positive, to keep living our lives and to enjoy however much time we had together.

I joined the early trial of Sativex in the hope that it could improve my quality of life, but I also thought it was important to do so as the chemotherapy and radiotherapy I was having had all been trialled by other people before it could be used safely. I thought it only right and proper that I followed in their footsteps and joined a trial to help prove a new drug which could benefit so many people in the future with a recurring glioblastoma.

I took the oral spray 10 times a day, and it was easy as I could take it wherever we were going, even while out for dinner. While I dont know whether I had Sativex or the placebo, since the trial finished in 2016, all my MRI scans have been clear.

"This new trial is so important as it will give people hope that there could be life beyond a glioblastoma diagnosis and that there are other treatments being trialled to support them to live their lives.

Principal Investigator, Professor Susan Short, Professor of Clinical Oncology and Neuro-Oncology at the University of Leeds, said:

The treatment of glioblastomas remains extremely challenging. Even with surgery, radiotherapy and chemotherapy, nearly all of these brain tumours re-grow within a year, and unfortunately there are very few options for patients once this occurs.

Cannabinoids have well-described effects in the brain and there has been a lot of interest in their use across different cancers for a long time now. Glioblastoma brain tumours have been shown to have receptors to cannabinoids on their cell surfaces, and laboratory studies on glioblastoma cells have shown these drugs may slow tumour growth and work particularly well when used with temozolomide.

Its really exciting that were now at the point where we can run a definitive, well-designed study that will tell us the answer to whether these agents could help treat the most aggressive form of brain tumour. Having recently shown that a specific cannabinoid combination given by oral spray could be safely added to temozolomide chemotherapy, were really excited to build on these findings to assess whether this drug could help glioblastoma patients live longer in a major randomised trial.

Dr David Jenkinson, Interim CEO at The Brain Tumour Charity, which is funding the trial, said:

We hope this trial could pave the way for a long-awaited new lifeline that could help offer glioblastoma patients precious extra months to live and make memories with their loved ones.

With so few treatments available and average survival still so heartbreakingly short, thousands affected by a glioblastoma in the UK each year are in urgent need of new options and new hope.

We know there is significant interest among our community about the potential activity of cannabinoids in treating glioblastomas, and were really excited that this world-first trial here in the UK could help accelerate these answers. The recent early-stage findings were really promising and we now look forward to understanding whether adding Sativex to chemotherapy could help offer life-extension and improved quality of life, which would be a major step forward in our ability to treat this devastating disease.

But we also know that for many, this trial wont come soon enough. In the meantime, while other cannabis-based products may help alleviate symptoms, there is insufficient evidence to recommend their use to help treat brain tumours. For anyone considering using cannabis-based products or other complementary therapies, its vital that you discuss these with your medical team first, as they could interact with other treatments such as anti-epileptic medicines or steroids.

Anyone affected by a glioblastoma can speak to us for support and information on 0808 800 0004 or by emailing support@thebraintumourcharity.org. If you need someone to talk to, were here for you.

Professor Pam Kearns, Director of the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham, which is co-ordinating the trial, said:

Our mission at the CRCTU is to translate cutting-edge science and research into improved patient care by identifying novel therapies that will save lives. It is vital that trials like this, investigating the role cannabis or the chemicals in it can play treat cancer, are carried out.

Read the original:

Major UK trial to assess whether cannabis-based drug could extend life for thousands with aggressive brain tumours - The Brain Tumour Charity

HOUSTON, Aug. 3, 2021 /PRNewswire/ --RESA Power, LLC, a market leader in power systems electrical testing, transformer services and life extension solutions for power distribution equipment, has announced the acquisition of EPIC Energy Solutions, LLC.

Based in Cleveland, OH, EPIC Energy Solutions (EPIC) has been providing electrical testing services for over a decade in Ohio and western Pennsylvania. EPIC specializes in offering preventative maintenance, turnkey operations including power equipment supply and installation, and acceptance testing.

Mark Angus, Chief Growth Officer at RESA Power, commented on the acquisition, "We have been following Garth and his team at EPIC for a long time, and been very impressed with their dedication and commitment to their customers. EPIC Energy Solutions fits nicely into our operational footprint and overlaps very well with our existing service locations in Michigan, New York, and Kentucky. As a result, both RESA's and EPIC's customers will enjoy the benefits of our enhanced combined capabilities."

Garth Paul, CEO and Owner of EPIC Energy Solutions added, "I'm very proud of the hard work and commitment from our team at EPIC over the last decade. We are fortunate to have earned the trust and loyalty of our customers, many of whom have been with us since we started. I'm now very excited about the opportunity to team up with RESA and offer our customers a significantly expanded portfolio of engineered products and NETA testing services."

About RESA Power, LLC

RESA Power, a portfolio company of Blue Sea Capital, is a market leader in power systems services and life extension solutions for power distribution equipment used in mission critical environments. With locations across the United States and Canada, RESA Power is uniquely capable of ensuring our customers' critical power systems are safe, reliable, and operating at peak efficiency. The technicians and engineers at RESA are experts in testing and servicing transformers, relays, breakers and other key components of power distribution and control systems. RESA also provides quick turn-around custom manufactured or retrofit switchgear & breaker solutions and maintains an extensive inventory of obsolete and hard-to-find components. For more information about how to join the RESA Power group, visit https://www.resapower.com

Home

Media contact:

Julia Baranava

Marketing Manager

832-900-8343

315611@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/resa-power-expands-its-electrical-testing-capabilities-in-the-midwest-region-301346032.html

SOURCE RESA Power

Follow this link:

RESA Power Expands its Electrical Testing Capabilities in the Midwest Region - inForney.com

The Navy League of the United States this week presented Washingtons premier annual exposition of all things maritime.

Called Sea-Air-Space 2021, the three-day event was a reminder that defending the nation is big business.

Over 300 vendors exhibited, and all the available space in the cavernous Gaylord National Resort & Convention Center was sold out.

Viewing the diverse wares being offered and the size of the crowdsthousands every daya casual observer could easily conclude that happy days are here again for the nations sea services.

Does the Navy really need a successor to the Burke-class destroyer? Probably not.

However, the recent pronouncements of Navy leaders suggest otherwise.

On the eve of the exposition, Chief of Naval Operations Admiral Michael Gilday observed, We cant really afford to have a Navy bigger than the one that we can sustainBased on our current budget, I believe the analysis shows we can afford a fleet of around 300 ships.

It wasnt so long ago that the Trump administration was talking about building out the fleet to 500 manned and unmanned warships by 2045.

China currently has 360 warships in its own Navy, and looks likely to surpass 400 in the near future.

Chinas maritime aspirations lie mostly close to home, whereas the smaller U.S. Navy is expected to police the entire globe.

If that sounds like an impossible task with barely 300 vessels, the Navys most recent internal budget guidance to the fleet suggests the mismatch between capabilities and strategy will be getting worse in the future.

That guidance states, The Navy cannot afford to simultaneously develop the next generation of air, surface and subsurface platforms and must prioritize these programs balancing the cost of developing next generation capabilities against maintaining current capabilities.

Theres nothing new about the budgetary tension between readiness and modernization, but the guidance seems to indicate that Americas Navy will not be able to stay ahead of China in all measures of military capability.

Something will have to go.

The CNOs assessment that his service cant afford to sustain a fleet of more than 300 warships, meaning manned warships, is a clear signal that force structure will be the first victim of budgetary constraints.

Even with the sizable budget increases of the Trump years and the more recent move of Senate committees to provide a bigger military budget than the Biden White House requested for next year, Americas Navy isnt going to grow much.

So the last administrations plans for a 500-ship Navy were stillborndead virtually from the moment they appeared.

Maintaining a high state of readiness even in a 300-ship fleet will be challenging, but that is the top priority of every U.S. military service, so we can expect operations and maintenance accounts to remain adequately funded going forward.

With force structure more or less static and readiness the highest service priority, that leaves modernizationthe replacement of aging warships and aircraft with new technologyas the big question mark in Navy plans.

The Biden administrations budget request for the fiscal year commencing October 1 was a bit of a shock as far as naval modernization is concerned.

The Navy only requested construction funds for four combat vesselstwo subs, a destroyer and a frigateplus four other ships, while proposing to retire a larger number of vessels, mainly surface combatants.

This move ostensibly would free up money for modernization in future years, but Congress is balking at some of the retirements so when the smoke clears weapons accounts will still be under pressure in the budget.

The Navys budget guidance makes clear that supporting nuclear deterrence will remain its top modernization priority, so the next-generation Columbia ballistic-missile submarine, life extension of its D5 missiles, and a new nuclear command-and-control aircraft are not in danger.

There also seems to be no inclination in the Pentagon or on Capitol Hill to cut the other type of undersea warship, attack subs, below a construction rate of two per year.

So production of the Virginia-class attack sub equipped with a new midship payload module to multiply the vessels cruise-missile capabilities against land and maritime targets will also stay on track.

Thus the cuts, at least as far as warships are concerned, will come in the surface fleet.

Trying to delay construction of aircraft carriers would provoke a firestorm of criticism on Capitol Hill; the Navy only builds one every five years, and large-deck, nuclear-powered carriers remain the signature expression of American military power.

No warship is more useful in an overseas crisis.

Having sent ambiguous signals about its future warfighting plans, the Marine Corps shouldnt be surprised that construction of amphibious vessels looks like a billpayer in Navy plans.

Its also a little hard to understand why the Navy wants to buy frigates that are much less capable than its destroyers for a price-tag that is nearly as high per ship, but having just commenced the Constellation frigate program, the Navy isnt likely to now change its mind.

That leaves the destroyers.

A budgetary competition is emerging between the current class of Arleigh Burke vessels and a proposed next-generation destroyer designated DDG(X).

Congress appears much more favorably disposed to continuing production of the Burkes than embarking on the larger DDG(X).

The Navy says it needs more onboard volume and power generation for future weapons on its destroyers, but so many features of DDG(X) are borrowed from the Burkes that legislators arent so clear on why the Navy needs to pursue all the uncertainties of a new hull design.

So heres my prediction: faced with inadequate funding for modernization, the Navy will decide it can live without a next-generation destroyer.

It will bow to congressional pressure to keep Burke-class destroyers in production, perhaps in a somewhat larger Flight IV configuration, and figure out how to do its job without yet another new warship program.

That is the lowest-risk approach to modernizing the surface fleet, and the path of least resistance in the political system.

Read the rest here:

The Navy Says It Cant Afford To Fully Modernize. So What Should It Give Up? - Forbes

At 4 PM EST last Friday, the trade deadline closing bell rang, and when it did, those of us on the outside looking in were glued to Twitter to learn about the trades that had been completed right before the countdown clock hit zero. It usually takes a little while to learn about all the transactions that get completed in those final minutes. Plenty of players found new homes, but the surprise of the afternoon was that when the dust settled, Trevor Story was still a member of the Colorado Rockies.

The Rockies are 21 games out of first place in their division. Per our Playoff Odds (and good sense), their chances of reaching the postseason this year are a big fat zero, and have been for some time. They also play in the toughest division in baseball, with the Dodgers and Padres looking like teams that will sit at the top of the National League West standings for years to come. The Rockies need to make drastic changes in order to take on those two powerhouses (and the Giants arent exactly slouches), and those changes should have begun on Friday. Instead, they sat on their hands, losing a golden opportunity to kick-start a return to competitiveness for a franchise that has reached the playoffs just five times in 28 seasons and has still never won a division title.

Colorado did make one trade during deadline week, sending reliever Mychal Givens and his expiring contract to the Reds for a pair of fringe pitching prospects. But thats not starting a re-build or, if that term strikes you as too strong, re-tooling the roster so much as it is taking care of some necessary chores. And while Givens departed, there were other players rumored to be on the move who ended up staying put. Holding on to Jon Gray is a curious decision. The team hasnt earned the benefit of anybodys doubt, but lets give it to them in the case of Gray, who has publicly stated his desire to stay in Colorado. Player comfort leads to better player performance, and if they can sign him to an extension, this makes sense. The jury can still be out on that one. But Daniel Bard still being the teams closer on August 1 is significantly more difficult to explain. Again, there is surely some loyalty here, and the Rockies deserve some credit for getting Bard back on the mound and finding a decent late-inning option in the process, but as a free agent following the 2022 season (a season in which Colorado will almost certainly not contend), the club just squandered Bards peak trade value, and yet another chance to boost a farm system that is among the worst in baseball.

Rockies leadership tries to say the right things (well ignore the clubs strange insistence that this is a very talented team that has simply underperformed), like that they are excited about the young core in their starting rotation, and that they want to spend this winter trying to improve the offense. You know, the offense that could use a guy like Nolan Arenado, who was jettisoned in a move that seemed to be at least somewhat driven by a clash with management just two years after signing a Rockie-for-life extension. Or the offense that would benefit from a contact-driven machine like DJ LeMahieu. At least there, owner Dick Monfort admitted the team erred by allowing LeMahieu to sign elsewhere when he inked a two-year deal with the Yankees prior to the 2019 season that was below industry expectations. But trying to say the right thing hasnt translated to good process or results, and now we can add Trevor Story to the list of playoff-caliber players looking forward to getting out of Denver.

Maybe they really do believe that the compensatory draft pick theyll receive when Story departs in free agency after being tagged with a qualifying offer is better than the deadline offers they had in hand. Storys 2021 performance certainly led to a depressed market for the shortstop. But its nearly impossible to believe that no team was willing to offer a prospect, or a package of prospects, with greater value than a pick in the 30s. Not to mention that that player (or players) would immediately become a Rockie and hopefully begin his path to the big leagues, while the player Colorado gets with a 2022 compensation pick wont even begin his pro career until a year from now, thus further delaying any hope for a return to competitiveness.

Despite their struggles as a franchise, the Rockies have never had a full front office turnover. The people in charge can be traced, family-tree style, to the teams origins. In terms of their strategy, behavior and responsiveness, other clubs have found them somewhere between confusing and frustrating to work with for years. There is nothing wrong with zigging when other teams zag, but at times the Rockies operate with seemingly no understanding of the Major League Baseball rule set, or what must be done within it to build a good roster.

And to be clear, I feel bad for Bill Schmidt, the teams vice president of scouting who currently serves as the interim general manager. With front office personnel departing the organization left and right over the last 12 months, he was put in an exceptionally difficult spot. Hes a well-respected talent evaluator and a well-liked person who was placed in an absolutely untenable situation; its like being made captain of the Titanic, but only after it hits the iceberg. I cant help but think that his activity (or more accurately, unforgivable inactivity) during deadline week rests on the shoulders of Monfort, who at times seems to care more about optics than winning. Those optics took a severe hit when a visibly upset Story expressed his frustration and confusion with the situation, talked about the toll it has taken on his on-field performance, and pulled himself from Fridays lineup.

Bud Black spoke after the deadline about how the team needed to score more runs. Hes certainly not wrong, as the Rockies entered the week 10th in the National League in on-base percentage and ninth in slugging despite playing half of their games at Coors Field. No position player has accumulated as much as 2 WAR on the season; their best qualified hitter has been Brendan Rodgers, who has a wRC+ of 103. The third overall pick in the 2015 draft, at age 24 Rodgers feels like hes begun to turn a corner. His wild approach is now merely aggressive, and the power potential is starting to show up in games. Hes beginning to look very much like a building block kind of player and he doesnt reach free agency until after the 2025 season. But based on what weve seen from the Rockies over the past five years, and their inability to project anything close to a competent organization, chances are much better than hell just become the next disillusioned, talented infielder looking for a way out of the Mile High City.

Visit link:

The Rockies Went Backwards by Doing Nothing - FanGraphs

Arlington, Texas Lumen Technologies, one of the worlds leading network providers, and the Texas Rangers Baseball Club today announced their partnership extension through the 2021 season.

Lumen Technologies currently acts as the Texas Rangers exclusive technology provider for infrastructure and telecommunications at Globe Life Field. Lumen works to deliver scalable, high-bandwidth connectivity for critical data and apps via a flexible, on-demand networking architecture that intelligently adjusts to real-time capacity needs.

Lumen has been a tremendous partner in helping us deploy a technology infrastructure at Globe Life Field that will serve us well in enabling the rapid evolution of technology for years to come, said Mike Bullock, Texas Rangers VP of Information Technology.

As a brand-new facility with the latest innovations in technology, Globe Life Field is among the most technologically advanced stadiums today. The ballpark regularly connects nearly 14,000 devices, a number that increases to over 40,000 devices on game days.

Lumen Technologies solutions at Globe Life Field include,

The Rangers first approached Lumen in 2017 to provide a variety of services and cloud technologies as part of the Globe Life Field construction project.

Lumen is guided by our belief that humanity is at its best when technology advances the way we live and work. With approximately 450,000 route fiber miles and serving customers in more than 60 countries, we deliver the fastest, most secure platform for applications and data to help businesses, government and communities deliver amazing experiences.

Learn more about the Lumen network, edge cloud, security, communication and collaboration solutions and our purpose to further human progress through technology at news.lumen.com/home, LinkedIn: /lumentechnologies, Twitter: @lumentechco, Facebook: /lumentechnologies, Instagram: @lumentechnologies and YouTube: /lumentechnologies. Lumen and Lumen Technologies are registered trademarks in the United States.

See more here:

Lumen Technologies and Texas Rangers extend partnership through end of 2021 season - MLB.com